Dr. Chhabra did his Masters in Biotechnology from Guru Nanak Dev University, Amritsar, in 1995, and PhD in Biotechnology from Central Drug Research Institute (CDRI), Lucknow, in 2001. After completing his PhD degree, Dr. Chhabra joined University of Connecticut Health Center (UCHC), Farmington, Connecticut, as a post doctoral fellow, in 2002. Dr. Chhabra served as an Assistant Professor of Medicine in the Department of Medicine from 2008-2017, and in the Stem Cell Institute from 2010-2017, at the UCHC. In June 2018 Dr. Chhabra joined Amity University Haryana (AUH) as Professor & Director of the Stem Cell Institute. Dr. Chhabra has cross-disciplinary research expertise in the fields of human cancer immunology and immunotherapy, human pluripotent stem cell (hPSC) research, and molecular microbiology. His work on human cancer immunology and immunotherapy is aimed at developing an effective cancer immunotherapy approach, utilizing active-specific immunization as well as T cell receptor (TCR)-engineered anti-tumor T cell-based adoptive transfer-based approaches. His work on hPSC involves generation of donor-specific induced pluripotent stem cell (iPSC) lines and utilization of these iPSC lines to generate functional immune effectors, such as effector T cells and antigen presenting cells (APC). Among Dr. Chhabra`s notable research contributions in the field of human cancer immunology and immunotherapy include, creation of donor-specific MHC class I restricted anti-tumor T cells by engineering human peripheral blood-derived T cells with a melanoma patient`s CD8+ CTL-derived MHC class I restricted transgenic T cell receptor (TCR). Dr. Chhabra has also identified a cell intrinsic, caspase-independent, mitochondria-centric cell death pathway involved in activation induced cell death (AICD) of human primary anti-tumor T cells, with an objective to generate anti-tumor T cells that will withstand premature AICD to sustain longer in the physiology and produce better clinical outcomes. Among his noteworthy contributions in the field of human pluripotent stem cell research include generation of iPSC lines from peripheral blood-derived dendritic cells (DC) of young and elderly individuals, utilizing non-integrating viral vector-based approaches. Dr. Chhabra has also developed methods to differentiate human iPSC lines into hematopoietic stem cell (HSC) precursors and functional APC. Given that the host immune system declines with age, quality as well quantitatively, iPSC-derived naïve immune effectors have significant translational implications towards developing personalized cancer immunotherapy approaches. Dr. Chhabra has published more than thirty manuscripts in prominent international peer-review journals. His research work has been widely cited and has earned him awards and accolades at international platforms, including Overseas Fellow of Royal Society of Medicine membership. Dr. Chhabra`s research was supported by several research grants, including three independent grants on which he served as the Principal Investigator, with a total funding amount of $925,000. Dr. Chhabra, also serves as an Editor/Editorial Board Member for several prominent research journals, including Scientific Reports, Onco-Targets & Therapy and Stem Cell Discovery Journal. In addition, he also serves as a peer-reviewer for several reputed international research journals, including Journal of Immunology, Journal of Leukocyte Biology, Vaccine and Expert Opinion on Therapeutic Targets. At the Amity Stem Cell Institute, Dr. Chhabra is building an educational as well as cutting edge research program in Molecular Medicine and Stem Cell Technology (MMSCT), with an overall objective to build an ecosystem that not only fosters cutting edge research, but also produces world class researchers and scientists in India.